Skip to content
Brand AI

Sinopharm Group

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile3 entries

  1. 2021

    Medical specialists warn against Sinopharm vaccine use in Sri Lanka

    Issue disclosure

    The Association of Medical Specialists warned against using the Sinopharm vaccine in Sri Lanka, citing an expert panel's conclusion that the available data were insufficient to determine its safety, efficacy and immunogenicity.

    Source excerpt

    • In the backdrop of an independent panel of medical experts cautioning against administering the controversial Chinese manufactured Covid-19 Sinopharm jab over “safety and efficacy” concerns, a key body of eminent medical specialists last week warned of the adverse fallout of using an unproven vaccine in Sri Lanka.
    • “As the expert medical panel concluded there was insufficient data provided to make a determination on the safety, efficacy and immunogenicity of the Sinopharm vaccine, it was accordingly concluded that this vaccine should not be used in Sri Lanka under the present circumstances”, Dr. Lalantha Ranasinghe, the president of the prestigious body of medical professionals, said.
    Source

  2. 2017

    Substandard DPT vaccine batch produced by Wuhan Institute of Biological Products

    Chinese regulatory sampling found that a DPT vaccine batch produced by Sinopharm’s Wuhan Institute of Biological Products failed potency requirements. Regulators reported that 400,520 doses were affected. The stated cause was a temporary filling-equipment malfunction that made the vaccine suspension uneven. Unused doses were recalled and destroyed, and the subsidiary was fined and required to strengthen equipment maintenance, filling procedures, training and quality controls.

    Source

  3. Ineffective DPT vaccine incident (2017)

    Source